FIG. 1



Day 0
Day 1
Day 8
Day 12
Tolerance induction
Challenge

FIG. 2



Lymph Nodes - OT-I
OT-I cells (% among CD3+CD8+)
Spleen - OT-I
OT-I cells (% among CD3+CD8+)
Lymph Nodes - OT-II
OT-II cells (% among CD3+CD4+)
Challenge Control
Tolerance Control
B cell-Endo
B cell-SOZ

FIG. 3



Spleen
IFNg+CD44+
(% among TCRVa2+CD45.2+)
90
80
70
60
50
40
***
*
***
Challenge Control
Tolerance Control
B cell-Endo
B cell-SOZ
Spleen
MFI IFNg
(among CD44high
TCRVa2+CD45.2+)
15000
10000
5000
0
***
***
****
Challenge Control
Tolerance Control
B cell-Endo
B cell-SOZ

FIG. 4



Spleen
Number of ELISpots
600
400
200
0
**
****
Challenge Control
Tolerance Control
B cell-Endo
B cell-SOZ

FIG. 5



Spleen
(OT-I – CD3+CD8+)
Lymph Node
(OT-II – CD3+CD4+)
1.47%
Challenge
0.79%
Tolerance
1.54%
B cell-
Endo
0.32%
B cell-
SQZ
0.77%
Challenge
0.13%
Tolerance
0.57%
B cell-
Endo
0.15%
B cell-
SQZ
TCRVa2
CD45.2

FIG. 6



IFN-γ Responsive OT-I T Cells in Spleen
79.6%
Challenge Control
67.8%
Tolerance Control
77.6%
B cell-Endo
54.8%
B cell-SQZ
IFN-γ
CD44

FIG. 7




FIG. 8




FIG. 9




FIG. 10



Challenge Control
Naïve
SQZ-OVA
Tolerance Control
20.8%
1.49%
1.52%
2.55%
87.1%
1.37%
15.5%
26.0%
OT-I T cells (CD45.2)
CD8+ T Cells
IFN-γ
CD44

FIG. 11A




FIG. 11B




FIG. 12A

FIG. 12B

